Psychedelic Therapy Scrutinized by FDA Advisory Committee?
JAMA July 30, 2024 DOI: 10.1001/jama.2024.13370 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Viewpoint or commentary Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Advisory committee Family medicine Management |
| Citations | 20 |
| Key points | Argues that the advisory committee's decisions on MDMA-assisted therapy carry significant implications for the trajectory of psychedelic research. |
Abstract
This Viewpoint analyzes the Psychopharmacologic Drugs Advisory Committee’s decisions regarding 3,4-methylenedioxymethamphetamine–assisted therapy and what they mean for psychedelic research.